IBB vs TCAF: Holdings Overlap
iShares · 254 holdings · $9.3B · as of 2026-03-31
TCAFT. Rowe Price Capital Appreciation Equity ETF
T. Rowe Price · 92 holdings · $8.3B · as of 2026-03-31
How similar are IBB and TCAF?
iShares Biotechnology ETF (IBB, by iShares) holds 254 positions; T. Rowe Price Capital Appreciation Equity ETF (TCAF, by T. Rowe Price) holds 92. They have 13 holdings in common, and by portfolio weight the two funds are 5.3% identical. In practical terms the pair is lightly overlapping, with most of each portfolio distinct.
- Overlap by Weight
- 5.3%Sum of the smaller weight of each shared holding
- Shared Holdings
- 13IBB holds 254 · TCAF holds 92
- Weight in Shared Holdings
- IBB 19%·TCAF 6%Share of each fund's weight in stocks both funds own
Based on each fund's latest official holdings. How is this calculated?
What makes each fund different
Only in IBB
241 of 254 positions (80.4% of the fund) are not held by TCAF. Showing the top 30 by weight.
Sector Breakdown
| Sector | IBB | TCAF |
|---|---|---|
| Health Care | 91.0% | 17.6% |
| Information Technology | 0.0% | 30.5% |
| Consumer Discretionary | 0.0% | 12.1% |
| Utilities | 0.0% | 10.2% |
| Communication Services | 0.0% | 8.2% |
| Other Sectors | 0.0% | 17.9% |
| Unclassified | 8.9% | 3.3% |
Share of each fund's portfolio weight by GICS-style sector, compiled from issuer fund data and our own classification of the holdings, not the issuers' published sector charts. “Unclassified” is weight we could not classify (9% of IBB, 3% of TCAF).
Performance
| Fund | 1M | YTD | 1Y | 3Y (ann.) | 5Y (ann.) | 10Y (ann.) | Yield |
|---|---|---|---|---|---|---|---|
| IBB | -0.3% | +17.3% | +51.0% | +16.4% | +3.1% | +7.4% | 0.21% |
| TCAF | +3.1% | +12.1% | +18.5% | +18.6% | — | — | 0.45% |
Total returns including dividends, from adjusted daily closes as of 2026-08-07. 3Y/5Y/10Y are annualized. Yield is trailing-12-month distributions over the last close. Past performance does not predict future results.
Project the growth of $10,000 in IBB vs TCAF →
Shared Holdings(13)
The top 10 shared positions account for 92% of the overlap, led by Ascendis Pharma A/S, ALNY and CYTK.
| Ascendis Pharma A/S | 0.96% | 1.23% | 0.96% |
|---|---|---|---|
 ALNYAlnylam Pharmaceuticals Inc. COM | 3.99% | 0.79% | 0.79% |
 CYTKCytokinetics Incorporated | 0.73% | 1.11% | 0.73% |
 PCVXVaxcyte Inc COM | 0.75% | 0.44% | 0.44% |
 BNTXBioNTech SE, ADR | 0.66% | 0.40% | 0.40% |
 APGEApogee Therapeutics Inc. COM | 0.37% | 0.86% | 0.37% |
 GILDGilead Sciences Inc. COM | 7.75% | 0.35% | 0.35% |
 ACLXArcellx Inc COMMON STOCK | 0.47% | 0.31% | 0.31% |
 BIIBBiogen Inc COM | 2.46% | 0.28% | 0.28% |
 CGONCG Oncology Inc. COM | 0.32% | 0.26% | 0.26% |
 KYMRKymera Therapeutics Inc COM | 0.53% | 0.17% | 0.17% |
 ERASErasca Inc COM | 0.28% | 0.14% | 0.14% |
 DYNDyne Therapeutics Inc. COM | 0.20% | 0.10% | 0.10% |
Frequently Asked Questions
How much do IBB and TCAF overlap?
IBB and TCAF overlap by 5.3% of portfolio weight. They share 13 holdings (IBB holds 254 positions and TCAF holds 92), based on each fund's latest SEC-reported holdings.
Is it redundant to own both IBB and TCAF?
The two portfolios are 5.3% identical by weight. Owning both is not redundant. Most of each portfolio is distinct, so the funds can serve different roles.
What are the biggest shared holdings of IBB and TCAF?
The largest positions held by both funds are Ascendis Pharma A/S, ALNY, CYTK, PCVX and BNTX. Together the top 10 shared positions account for 92% of the total overlap.
What does IBB own that TCAF doesn't?
241 positions (80.4% of IBB) are unique to IBB, led by AMGN, VRTX and REGN. In the other direction, 79 positions (93.4% of TCAF) are unique to TCAF.